Prof. Dr Iris Löw-Friedrich (born in 1960, German citizen) was appointed Member of the Supervisory Board on 17 June 2014 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2019 on 19 June 2019 for a term of five years. Since 15 June 2021 she has been serving as chairwoman of the Supervisory Board. Her current term will expire at the end of the Annual General Meeting held in the year 2024.

Since March 2008, Prof. Dr Iris Löw-Friedrich is serving as Chief Medical Officer and Executive Vice President Development and Medical Practices of UCB S.A., Brussels (Belgium).

From 2001 to 2009, Prof. Dr Löw-Friedrich was a member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen.

From 1992 to 2000, Prof. Dr Löw-Friedrich held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion Roussel/Aventis, Bridgewater, NJ, USA.

Since April 2014, she has been Member of the Board of Directors at TransCelerate BioPharma Inc (Chairman of the Board of Directors from September 2015 until September 2017). TransCelerate BioPharma Inc is a non-profit organisation with membership of 20 major life science companies, including UCB. Since April 2019, she is also a member of the Board of Directors of PhRMA Foundation in Washington DC (US).

Since May 2016, Prof. Dr Löw-Friedrich has been serving as Member of the Supervisory Board of Fresenius SE & Co. KGaA. Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000.

She studied medicine at the University of Frankfurt/Main, receiving her doctorate from this university in 1985.

Prof Dr Iris Löw-Friedrich is independent in the opinion of the Company. Her position on the Executive Board of UCB S.A., which has a business relationship with Evotec SE, does not constitute dependency. Business relationships constitute a material and prolonged conflict of interest only in exceptional cases. The Supervisory Board has no influence on the volume of orders or the continuation or expansion of business relationships. This is the responsibility of the Management Board of Evotec SE, which not only represents the Company (section 78 of the German Stock Corporation Act (AktG)), but also makes decisions on these matters under its own responsibility (section 76, paragraph 1 of the German Stock Corporation Act (AktG)). There is also no intersecting executive body position.

Latest update: June 2022

Mr Roland Sackers (born in 1968, German citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. Since 15 June 2021 he is Vice Chairman of the Supervisory Board. His current term will expire at the end of the Annual General Meeting held in the year 2024.

Mr Sackers has been serving as Chief Financial Officer of QIAGEN N.V. since January 2004. In this position, he is responsible for developing and executing the long-term financial planning, which is the foundation for the company’s accelerated growth strategy.

Prior to joining QIAGEN in 1999, Mr Sackers served as Auditor at the auditing company Arthur Andersen.

Mr Sackers received his master’s degree in Business Administration from the University of Münster.

He represents QIAGEN as board member of BIO Deutschland e.V. Mr Roland Sackers (CFO of Qiagen N.V.) is independent. Qiagen N.V. has no significant business relationship with Evotec SE, and no other circumstances leading to dependency are apparent.

Latest update: June 2021

Mrs Camilla Macapili Languille (born 1983, Canadian citizen) was appointed Member of the Supervisory Board on 22 June 2022. 

Camilla Macapili Languille is an investment expert with some 20 years of experience in business development, asset management and M&A in Europe, North America and Middle East and North Africa (MENA). She has worked in various areas of corporate finance and principal investment, with a focus on healthcare, technology and industrial companies.

Camilla Macapili Languille leads the unit for Life Sciences investments at Mubadala Investment Company ("MIC"), a sovereign wealth fund based in Abu Dhabi with total assets of some USD 250 billion. This unit invests in the international healthcare sector in the fields of pharmaceuticals, medical devices, life-science tools and diagnostics, healthcare IT, services, biotechnology and veterinary medicine, and in various asset classes (private equity, listed shares, funds). She is currently a member of the Direct Investments Committee of Mubadala and has a seat on the board of PCI Pharma, Rodenstock and the Envision Pharma Group.

Before founding the Life Sciences investment team, Camilla Macapili Languille managed the MIC investments in Advanced Micro Devices (“AMD”) and Globalfoundries and was responsible for business development in the technology sector. She also led MIC investments in two power plants in Oman and Algeria, a goldmine in Columbia and a district cooling plant, Tabreed, and was responsible for business development for MIC in the field of conventional energy.

Before joining Mubadala, Camilla Macapili Languille worked in M&A for Daiwa Capital and Société Générale in Paris, France, where she specialised in cross-border transactions in various sectors. She also worked as an investment manager at the London headquarters of the Virgin Group, where she managed the special situations portfolio, was involved in the establishment of Virgin Healthcare, and was a director of several companies.

Camilla Macapili Languille began her career in healthcare M&A at JPMorgan in New York and London, where she focused on pharma and biotech.

Camilla Macapili Languille holds a Bachelor of Economics & Political Science degree from Columbia University, which she completed summa cum laude in 2004. She grew up in an international environment and has lived in 14 countries on four continents. She speaks fluent English and French.

Her long-standing, wide-ranging experience in the pharmaceutical and biotech sectors mean she has extensive knowledge of the industry. Her particular investment expertise makes Ms Macapili Languille an ideal addition to the range of competences represented on the potential Supervisory Board of Evotec SE.

Latest update: June 2022

Dr Mario Polywka (born in 1963, British citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. His current term will expire at the end of the Annual General Meeting held in the year 2024.

Dr Polywka retired from the Management Board of Evotec AG effective 31 December 2018. Until then, he served as member of the Management Board and Chief Operating Officer of Evotec AG since 28 November 2007.

In 1991, he was a founding chemist of Oxford Asymmetry International plc (OAI), became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr Polywka was appointed Chief Operating Officer and in 2000 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000 he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr Polywka ran a number of spin-out companies from Oxford and Southampton Universities.

Dr Polywka received his Bachelor’s degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with post-doctoral studies on the biosynthesis of Penicillin with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994.

Dr Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis.

In May 2017, Dr Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc. and in September 2017, Dr Mario Polywka also joined the Board of Directors of Exscientia Ltd. In September 2019, Dr Polywka was appointed Non-Executive Director at the UK biotech company Orbit Discovery, and has accepted a position as Senior Advisor with MCF Corporate Finance. He has served as Non-Executive Director at UK based company C4X Discovery Holdings PLC since December 2021.

Dr Mario Polywka, who served as COO of Evotec until 31 December 2018 and who was elected to the Supervisory Board on the recommendations of a group of shareholders who together hold more than 25% of the total number of voting rights in the Company, is regarded as not independent.

Latest update: June 2022

Dr Elaine Sullivan (born in 1961, British citizen) was appointed Member of the Supervisory Board on 09 June 2015 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2019 on 19 June 2019 for a term of five years. Her current term will expire at the end of the Annual General Meeting held in the year 2024.

From April 2020 until October 2021, Dr Sullivan was CEO of Curadh Pharmaceuticals. From 2015 to 2019, Dr Sullivan was Chief Executive Officer of Carrick Therapeutics Ltd, a European oncology company, which she continues to support as Executive Entrepreneur and Advisor to the Board of Directors.

Elaine Dr Sullivan has worked as part of top management teams in R&D at Eli Lilly and AstraZeneca. She has over 25 years of international experience working in the Pharmaceutical industry in the USA and the UK. From 2011 to 2014, she served as Vice President Global External Research and Development at Eli Lilly & Company, Inc., Indianapolis, IN, USA, where she led a global workforce delivering access to business critical external innovation. She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly’s Capital Fund partners.

Prior to joining Eli Lilly, Dr Sullivan held various positions in the area of drug discovery and development at AstraZeneca from 1995 until 2010, including Vice President R&D, New Opportunities, from 2007 to 2010. In this role, she established and led AstraZeneca‘s virtual Therapy disease function which pinpointed new disease areas and created new therapeutic applications for multiple molecular entities and advanced them into the clinic. During her career, she gained extensive knowledge of various aspects of drug discovery and development having developed new molecules in virology, cancer, ophthalmology and respiratory and inflammation. Furthermore, she has particular expertise in origination, development and execution of innovative partnerships.

Since July 2015, Dr Elaine Sullivan has been serving as Non-executive Director of the IP Group plc and since May of 2022 on the Board of Directors of Nykode Therapeutics AS. Dr Sullivan holds a doctorate in Molecular Biology and Virology from the University of Edinburgh, UK, and a bachelor’s degree in Molecular Biology from the University of Glasgow, UK.

Dr Elaine Sullivan (the former CEO of Carrick Therapeutics Ltd) is independent. Evotec SE holds approximately 4.5% of the shares in Carrick Therapeutics Ltd., and it is not a significant partner of Carrick Therapeutics Ltd. at present.

Therefore, for two reasons there is no conflict of interest that could hinder the position of independence:

1. Evotec SE's participation rights in Carrick Therapeutics Ltd. are exercised by the Management Board of Evotec SE on its own responsibility pursuant to section 76 paragraph 1 of the German Stock Corporation Act (AktG). In particular, a member of the Supervisory Board has no influence on the voting on the resolutions of the shareholders of Carrick Therapeutics Ltd. (e.g. on any formal approval).
2. There is also no intersecting executive body position, nor are there any other significant connections to members of the company's Management Board through their involvement in other companies or organisations.

Latest update: June 2022

Dr Ulmer-Eilfort has more than twenty years’ experience in advising high-tech, pharmaceutical and media companies on the protection and marketing of their intellectual property rights. As a Partner with PSP München, she advises on a wide range of agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions. 

Previously, Dr Ulmer-Eilfort was a Partner with the international law firm Baker McKenzie where she was also a member of the Global Executive, chairing the Global Financial Committee and overseeing the budgeting process and budget controls worldwide.

Dr Ulmer-Eilfort’s leadership roles in both management and supervisory functions as well as her specialisation in the protection and marketing of intellectual property and corporate governance are an ideal qualification for her membership of the Supervisory Board of Evotec SE.

Dr Ulmer-Eilfort is to be considered as independent as she has no business relationship with Evotec SE and no other circumstances leading to dependency are apparent. She is chairwoman of the advisory committee of S4DX GmbH. Otherwise she is not a member of any statutory supervisory boards or similar domestic or foreign supervisory boards of commercial entities in accordance with Sec. 125 para. 1 sentence 5 AktG and recommendation C.14 of the German Corporate Governance Code as amended on 16 December 2019.

Latest update: January 2022